Study identifies Δ42PD-1 as novel therapeutic target for hepatocellular carcinoma immunotherapy


HKUMed researchers at AIDS Institute, Department of Microbiology and Department of Surgery, School of Clinical Medicine, and School of Biomedical Sciences discover the role of an isoformic programmed cell death protein 1 (PD-1), namely Δ42PD-1, in suppressing the function of killer T cells, which is a type of immune cells essential for killing cancer cells among hepatocellular carcinoma (HCC) patients.

White House reveals winter COVID-19 plans, more free tests

Previous article

Randomized trials demonstrate the safety of Ebola vaccine regimens in adults and children

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News